Nektar Therapeutics (NKTR) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving Nektar Therapeutics (NKTR) right now is Rezpegaldesleukin in atopic dermatitis: The lead program targets a large, competitive dermatology market. Q1 2026 revenue is ~$10.9M. If that keeps playing out, the setup is favourable; the risk to it is nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. No one can predict where NKTR trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Nektar Therapeutics (NKTR) higher?
Rezpegaldesleukin in atopic dermatitis
The lead program targets a large, competitive dermatology market. REZOLVE-AD Phase 2b maintenance data reported in February 2026 showed durable responses with both monthly and quarterly dosing, and the asset carries FDA Fast Track designation, setting up a planned Phase 3 program.
Alopecia areata expansion
REZOLVE-AA established Phase 2b proof-of-concept in severe-to-very-severe alopecia areata, giving rezpeg a second immuno-dermatology indication. Nektar plans to advance the molecule into Phase 3 in alopecia areata, broadening the addressable opportunity beyond a single disease.
Treg mechanism and broader pipeline
Rezpeg's regulatory T cell mechanism is being explored in type 1 diabetes as well, and Nektar retains earlier-stage assets including TNFR2 bispecific programs (NKTR-0165, NKTR-0166), NKTR-422, and IL-15 agonist NKTR-255, offering optionality if the Treg approach validates.
Strengthened balance sheet
An April 2026 financing pushed cash and investments to over ~$1B, extending runway to fund the planned pivotal trials. For a clinical-stage biopharma, capital adequacy through the next major readouts is a central input to whether programs reach their catalysts.
What could weigh on NKTR?
Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Rezpegaldesleukin's pivotal outcomes are binary and years away (initial Phase 3 readouts guided around 2028), and clinical or regulatory setbacks could sharply affect the shares. The atopic dermatitis and alopecia areata markets are crowded with established biologics such as Dupixent and JAK inhibitors, so commercial success is not assured even with a positive trial. Additional capital raises could dilute existing holders, and the stock has historically been volatile around data and trial news.
Where NKTR trades today
A forecast starts from where the stock actually is. These are NKTR's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for NKTR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a NKTR forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the NKTR guide and whether NKTR is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the NKTR outlook
The bottom line: what is driving Nektar Therapeutics (NKTR) is Rezpegaldesleukin in atopic dermatitis, with q1 2026 revenue at ~$10.9M. If that keeps playing out the setup is favourable; the risk is nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. No one can predict the price, so treat any NKTR forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around NKTR with Walnut
Use Nektar Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Nektar Therapeutics (NKTR)?
+
No one can reliably predict where NKTR will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Nektar Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive NKTR higher?
+
The main growth drivers are Rezpegaldesleukin in atopic dermatitis; Alopecia areata expansion; Treg mechanism and broader pipeline. Whether they play out is the real question, not a guaranteed path.
What are the risks to NKTR?
+
Nektar is pre-commercial, so it has no approved product revenue and continues to post operating losses funded by its balance sheet. Rezpegaldesleukin's pivotal outcomes are binary and years away (initial Phase 3 readouts guided around 2028), and clinical or regulatory setbacks could sharply affect the shares. The atopic dermatitis and alopecia areata markets are crowded with established biologics such as Dupixent and JAK inhibitors, so commercial success is not assured even with a positive trial. Additional capital raises could dilute existing holders, and the stock has historically been volatile around data and trial news.
Will NKTR stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Nektar Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is NKTR a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the NKTR "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.